Rosen Law Firm Urges Soleno Therapeutics Investors to Seek Class Action Participation

On October 20, 2025, the Rosen Law Firm, a renowned law firm specializing in investor rights, announced its ongoing examination of possible securities class action claims for investors of Soleno Therapeutics, Inc. (NASDAQ: SLNO). The investigation arises from allegations surrounding misleading business information that may have been disseminated to the investing public.

Why This Matters

Investors who purchased shares in Soleno Therapeutics could be eligible for compensation without experiencing any upfront costs, thanks to a contingency fee structure offered by the Rosen Law Firm. They are developing a class action aimed at compensating investors who may have suffered losses due to these potential misrepresentations.

What Prompted the Investigation

The inquiry follows an article published by Investing.com on August 15, 2025, which reported a significant drop in Soleno Therapeutics' stock price. The decline was triggered by a short report from Scorpion Capital, which expressed serious reservations about the company’s newly approved treatment for Prader-Willi syndrome, known as VYKAT XR. This report raised concerns regarding the safety of the treatment, suggesting it could face withdrawal from the market or a notable decrease in new prescriptions. Consequently, Soleno's stock plummeted by 7.4% on the same day and further dipped by 4.9% in subsequent trading.

Taking Action

Investors wishing to join the forthcoming class action are encouraged to visit Rosen Legal or contact Phillip Kim, Esq. at 866-767-3653 for additional information. By doing so, affected shareholders can begin the process of securing their potential claims.

The Importance of Qualified Legal Representation

The Rosen Law Firm strongly advises investors to choose legal counsel that has a proven track record in successfully leading securities class actions. Many law firms sending out notices may not offer comparable experience or resources and may lack actual litigation practice in such cases. Therefore, selecting competent counsel is imperative to navigating the complexities surrounding securities fraud and class actions.

Having represented investors globally, the Rosen Law Firm has an impressive history in securities class actions and shareholder derivative litigation. The firm has achieved significant settlements, notably securing the largest securities class action settlement involving a Chinese company at the time, and has consistently ranked among the top law firms in this field for several years. In 2019 alone, the firm recovered over $438 million for its clients, highlighting its commitment to fighting for investor rights.

Follow Us for Updates

Stay informed about the case and other developments in investor rights by following the Rosen Law Firm on LinkedIn, Twitter, and Facebook. Their extensive outreach and engagement through social media platforms ensure that investors remain updated on the status of this significant investigation.

Conclusion

This ongoing investigation by the Rosen Law Firm serves as a critical reminder for investors to stay vigilant and informed about their rights, especially in the wake of potentially misleading corporate communications. For those impacted by the situation surrounding Soleno Therapeutics, taking swift action could be vital in seeking recovery for their financial losses.